1. Clinical Overview
Ropinirole is a non-ergoline dopamine agonist that selectively stimulates D2, D3, and D4 dopamine receptors in the brain. It is a cornerstone therapy for Parkinson's disease (PD) and Restless Legs Syndrome (RLS) in the Indian market, valued for its efficacy in managing motor symptoms and its potential to delay the need for levodopa therapy. It helps correct the dopamine deficiency characteristic of PD.
| Onset | Duration | Bioavailability |
|---|---|---|
| Approximately 1-2 hours after oral administration. | Approximately 6 hours. | Approximately 50% (absolute bioavailability). |
2. Mechanism of Action
Ropinirole mimics the action of dopamine by directly stimulating postsynaptic dopamine receptors (primarily D2 subfamily) in the striatum and substantia nigra. This stimulation compensates for the depleted endogenous dopamine in Parkinson's disease, leading to improved motor control. In RLS, its mechanism is believed to involve modulation of dopaminergic pathways in the spinal cord.
3. Indications & Uses
- Idiopathic Parkinson's Disease (as monotherapy or adjunct to levodopa)
- Moderate-to-Severe Primary Restless Legs Syndrome (RLS)
4. Dosage & Administration
Adult Dosage: Parkinson's Disease: Start at 0.25 mg TID. Titrate weekly by 0.25 mg TID to target dose of 1 mg TID (3 mg/day). Max: 24 mg/day. RLS: Start at 0.25 mg once daily, 1-3 hours before bedtime. Titrate to 0.5 mg, then 1 mg, then 2 mg as needed, with at least 2 days between increments. Max: 4 mg/day.
Administration: Take with or without food. Taking with food may reduce nausea. For RLS, take 1-3 hours before bedtime. Do not crush or chew extended-release tablets (if applicable to other strengths). For the 1mg immediate-release tablet, swallow whole with water. Do not abruptly discontinue.
5. Side Effects
Common side effects may include:
- Nausea
- Dizziness
- Somnolence (daytime sleepiness)
- Headache
- Vomiting
- Fatigue
- Orthostatic hypotension (dizziness on standing)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Fluvoxamine (and other potent CYP1A2 inhibitors) | Markedly increases ropinirole AUC (up to 12-fold). Contraindicated in RLS. In PD, reduce ropinirole dose if co-administered. | Major |
| Ciprofloxacin (moderate CYP1A2 inhibitor) | Increases ropinirole AUC (~80%). Monitor and consider dose reduction. | Moderate |
| Estrogens (e.g., Hormone Replacement Therapy) | May decrease ropinirole clearance by ~35%. Monitor for increased side effects. | Moderate |
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedative effects. Increased risk of somnolence and sudden sleep onset. | Moderate |
| Dopamine Antagonists (e.g., Metoclopramide, Phenothiazines, Butyrophenones) | May diminish efficacy of ropinirole. Avoid concomitant use. | Moderate |
| Levodopa | Enhances therapeutic effect but may increase incidence of dyskinesias, hallucinations, and orthostasis. Levodopa dose may need reduction. | Moderate |
7. Patient Counselling
- DO take the medication exactly as prescribed. DO NOT stop abruptly.
- DO inform your doctor about all other medications, including OTC and herbal products.
- DO rise slowly from sitting/lying position to minimize dizziness.
- DO NOT drive or operate heavy machinery until you are certain the medication does not make you drowsy.
- DO report any new or increased urges (gambling, sexual, eating, shopping) to your doctor immediately.
- For RLS, take the tablet 1-3 hours before your usual bedtime.
8. Toxicology & Storage
Overdose: Nausea, vomiting, dizziness, visual hallucinations, hyperhidrosis, claustrophobia, chorea, palpitations, arrhythmias, hypotension, sedation, agitation. Severe overdose may lead to cardiac arrest.
Storage: Store below 30°C. Protect from light and moisture. Keep in the original blister pack or container. Keep out of reach of children.